||ORD SHS $0.25
||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
AstraZeneca Share Discussion Threads
Showing 10251 to 10268 of 10275 messages
|21st feb Berenberg 'buy' tp 5450p cut from 5500p|
|17th feb Jefferies buy tp 5250p up from 4800p|
|China MediTech And AstraZeneca Plc (NYSE: AZN) To Present Savolitinib Phase II Results At The Genitourinary Cancers Symposium 2017
|xd tomorrow morning for the 150p dividend|
|Will these recover after divi is payed ?|
|I guess Liberum hasn't been paying attention to the way in which immunoncology has panned out for BMS. It is, indeed, high risk. I think the market has, to some extent, priced that in. AZN under the new CEO has resurrected some of the previously shuttered research that might lead to effective cancer treatments but it has some way to go and they won't be blockbuster treatments in the way that the old ones were: they will be highly targeted and so naturally have a smaller potential market per treatment or combination of treatments.|
|Liberum: AstraZeneca has further to go
‘Gross mis-pricing’ of AstraZeneca (AZN) shares is over but Liberum sees another 10% in upside.
Analyst Roger Franklin retained his ‘buy’ recommendation but reduced the target price from £52.00 to £51.00.
The shares were trading up 0.4%, or 18p, at £46.45 at the time of writing. ‘We upgraded AstraZeneca at the end of November, concluding that the valuation priced little to nothing for the high potential immuno-oncology franchise,’ he said.
‘With the attractive valuation and reassurance from management on unchanged [lung cancer study] Mystic confidence, the stock is now up 10%. While the gross mispricing is now over, even after modestly trimming our price target on weak earnings, we do see another c.10% upside to our fair value with several catalysts to come pre-Mystic.
‘But the real prize is the high-risk/high-reward potential for immuno-oncology to work in all comers and across multiple-indicators, at which point AstraZeneca is a £60-plus stock in our view.’
|Have tbh, thought we were going under £40 here, just a little wrong!.
It's approx 2% of what I have invested so s welcome development.|
|Fairly tough resistance here (see main chart in header).|
|13th feb Liberum buy tp 5100p cut from 5200p|
|10th feb Cantor buy tp 4900p up from 4700p|
|AstraZeneca (AZN) Said to Weigh Sale of Some Drugs in U.S., Europe - Bloomberg
AstraZeneca (NYSE: AZN) is weighing the sale of older treatments in the U.S. and Europe, according to Bloomberg, citing people familiar with the matter.
Drugs under consideration include Pulmicort Respules for children's asthma and acid reflux drugs Nexium and Prilosec. It may also sell Arimidex for breast cancer and Atacand for high blood pressure. The value of the sale may range from a few hundred million to more than $1 billion.
|two more targets cut today...
7th feb JP Morgan neutral tp 4200p cut from 4300p
7th feb HSBC hold tp 4500p cut from 4700p|
|Sooner buy more GSK !!!|
|Astrazeneca still a 'buy' after profit warning, says Deutsche Bank
|6th feb ShoreCap sell tp 4000p downgrade from hold
6th feb Deutsche buy tp 5500p cut from 6000p|
3rd feb Credit Suisse underperform tp 4000p
3rd feb UBS buy tp 5000p
3rd feb JP Morgan neutral tp 4300p
2nd feb ShoreCap hold -
2nd feb Liberum buy tp 5200p
2nd feb Cantor buy tp 4700p
2nd feb ++++++ Results ++++++|
|Easy ones first.....Wimbledon final 2022?......that'll be Federer,he'll only be 40.|